AU2012211204B2 - Remedy for migraine headache - Google Patents

Remedy for migraine headache Download PDF

Info

Publication number
AU2012211204B2
AU2012211204B2 AU2012211204A AU2012211204A AU2012211204B2 AU 2012211204 B2 AU2012211204 B2 AU 2012211204B2 AU 2012211204 A AU2012211204 A AU 2012211204A AU 2012211204 A AU2012211204 A AU 2012211204A AU 2012211204 B2 AU2012211204 B2 AU 2012211204B2
Authority
AU
Australia
Prior art keywords
migraine
active ingredients
nicotine
tryptophan
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012211204A
Other languages
English (en)
Other versions
AU2012211204A1 (en
Inventor
Joseph Robert Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NICO WORLDWIDE Inc
Original Assignee
NICO WORLDWIDE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NICO WORLDWIDE Inc filed Critical NICO WORLDWIDE Inc
Publication of AU2012211204A1 publication Critical patent/AU2012211204A1/en
Application granted granted Critical
Publication of AU2012211204B2 publication Critical patent/AU2012211204B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012211204A 2011-01-26 2012-01-26 Remedy for migraine headache Ceased AU2012211204B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436370P 2011-01-26 2011-01-26
US61/436,370 2011-01-26
PCT/US2012/022788 WO2012103377A1 (en) 2011-01-26 2012-01-26 Remedy for migraine headache

Publications (2)

Publication Number Publication Date
AU2012211204A1 AU2012211204A1 (en) 2013-09-12
AU2012211204B2 true AU2012211204B2 (en) 2014-04-24

Family

ID=46581171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012211204A Ceased AU2012211204B2 (en) 2011-01-26 2012-01-26 Remedy for migraine headache

Country Status (8)

Country Link
US (1) US8618118B2 (enExample)
EP (1) EP2667711A4 (enExample)
JP (1) JP2014503592A (enExample)
CN (1) CN103501609A (enExample)
AU (1) AU2012211204B2 (enExample)
CA (1) CA2826019C (enExample)
EA (1) EA201370171A1 (enExample)
WO (1) WO2012103377A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106581045A (zh) * 2016-12-02 2017-04-26 郑州莉迪亚医药科技有限公司 一种治疗偏头疼的药物及其制备方法
CN106511984A (zh) * 2016-12-02 2017-03-22 郑州莉迪亚医药科技有限公司 一种用于偏头疼的药物及其制备方法
KR101982923B1 (ko) * 2017-07-05 2019-05-27 가천대학교 산학협력단 편두통 진단용 바이오마커 및 상기 바이오마커를 이용한 편두통 진단방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202635A1 (en) * 2008-02-08 2009-08-13 Stephen Michael Scott Delivery System, Application, and Method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010A (en) * 1849-01-09 Improvement in the manufacture of hats
US9020A (en) * 1852-06-15 Improved machine for peaking sheet-metal tubes
US2018A (en) * 1841-03-26 Joseph francis
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4665069A (en) 1985-04-02 1987-05-12 Barnett Rosenberg Analgesic composition and method of relieving pain
US4639465A (en) 1985-08-30 1987-01-27 Commonwealth Medical Corporation Of America Method and composition for relieving pain
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
WO1995022967A1 (en) * 1994-02-24 1995-08-31 Otsuka Pharmaceutical Factory, Inc. Analgesic activity enhancer
CA2127573A1 (en) * 1994-07-07 1996-01-08 Angela Christine Gedye Vasotonic treatment for migraines
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6268386B1 (en) 1998-06-25 2001-07-31 Marshall Anlauf Thompson Nicotine beverage
IT1320776B1 (it) 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
US20060105023A1 (en) * 2001-12-10 2006-05-18 Knight Joseph R Treatment of neurological disorders with nicotine
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
ITMI20041689A1 (it) 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20080139510A1 (en) 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
GB2450076B (en) * 2007-05-17 2012-09-26 Sis Science In Sport Ltd Nutritional composition
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
KR20110134510A (ko) 2009-04-02 2011-12-14 샤이어 엘엘씨 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202635A1 (en) * 2008-02-08 2009-08-13 Stephen Michael Scott Delivery System, Application, and Method

Also Published As

Publication number Publication date
CA2826019A1 (en) 2012-08-02
EP2667711A1 (en) 2013-12-04
EP2667711A4 (en) 2014-11-12
WO2012103377A1 (en) 2012-08-02
EA201370171A1 (ru) 2014-05-30
AU2012211204A1 (en) 2013-09-12
JP2014503592A (ja) 2014-02-13
US8618118B2 (en) 2013-12-31
US20130143903A1 (en) 2013-06-06
CN103501609A (zh) 2014-01-08
CA2826019C (en) 2017-08-01

Similar Documents

Publication Publication Date Title
Manton et al. Declining prevalence of dementia in the US elderly population
JP2023514559A (ja) 頭痛障害の幻覚剤処置
JP2026048849A (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
AU2016226006A1 (en) Method of treatment with tradipitant
Saeedi et al. Challenges and approaches of drugs such as memantine, donepezil, rivastigmine, and aducanumab in the treatment, control and management of Alzheimer's disease
Reiter et al. Melatonin therapy in fibromyalgia
US8618118B2 (en) Remedy for migraine headache
AU4836399A (en) Treatment for multiple sclerosis
Jitomir et al. The acute effects of the thermogenic supplement Meltdown on energy expenditure, fat oxidation, and hemodynamic responses in young, healthy males
Sandyk A drug naive parkinsonian patient successfully treated with weak electromagnetic fields
Kantarci et al. Effects of in utero exposure to valproate or levetiracetam on the seizures and newborn histopathology of genetic absence epilepsy rats
Gupta et al. Clinical evaluation of aphrodisiac activity of a novel ayurvedic formulation for treatment of male sexual disorders
Grant Side effects of therapies for brain tumours
Maarad et al. Stiff Person Syndrome With Positive Anti-glutamic Acid Decarboxylase (GAD) Autoantibodies.
RU2345778C1 (ru) Способ лечения расстройств эрекции у мужчин
US12246053B2 (en) ENU pharmaceutical composition for treating or preventing neuropathic pain
RU2826786C2 (ru) Способ лечения ночного перемежающегося приапизма
Teimouri et al. A Double-Blind, Placebo-Controlled Study of the Effectiveness of Mate Endurance TM Dietary Supplement on Sexual Satisfaction, Ejaculatory Control, and Distress in Men with Premature Ejaculation
US20180243251A1 (en) Composition and Method for Improving Cognitive Function
JP7746253B2 (ja) 性機能不全を処置するための方法
Henry et al. Perimenstrual headache: Treatment options
Upadhyay et al. Headache, primary headaches and their treatment
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
WO2022124935A2 (ru) Композиция для коррекции сексуальной дисфункции у мужчин
Egal et al. 188 buspirone-induced somnambulism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired